Pre-earnings brief
Reports
Thu, Oct 29, 2026
Est. EPS
—
Est. revenue
—
Implied move
±8.9%
EPS beat rate
75%
Eli Lilly and Company (LLY) is a major player in the health care sector, specifically in pharmaceuticals. The company focuses on developing innovative medicines for various conditions, including diabetes and cancer, which are critical areas in today's health landscape.
Last quarter
In Q2 2026, Eli Lilly reported an EPS of $8.38, significantly exceeding expectations by 39.36%. The stock reacted positively, gaining 4.86% the following day.
Management promises and guidance
EPS beat streak
5Q
EPS beat rate
75%
Avg EPS surprise
+9.67%
Avg 1-day reaction
+0.01%
Overall, investors are optimistic about Eli Lilly's upcoming earnings, given its strong performance in previous quarters. However, there are concerns about potential market saturation in key therapeutic areas.
Bull case
If Eli Lilly continues to outperform expectations, particularly in EPS and revenue growth, it could solidify its position as a market leader and drive further stock appreciation.
Bear case
On the other hand, if the company fails to meet earnings expectations or shows signs of slowing growth, it could lead to a significant decline in stock price, as seen in past quarters.
The print will turn on these.
Q1
What will the EPS be for Q3-2026?
Given the strong EPS surprises in previous quarters, this number will be crucial for investor confidence and stock performance.
Q2
How is Eli Lilly addressing competition in the diabetes treatment market?
Understanding the company's strategy in a competitive landscape will be key to assessing future growth potential.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±9.4%
Why consensus could be wrong
The Street may underestimate Eli Lilly's ability to maintain its market share in diabetes treatments, which could lead to stronger-than-expected revenue growth.
Supporting evidence
The company's recent innovations in diabetes care could drive sales beyond current expectations.
Options pricing suggests a significant move, indicating that traders are anticipating more volatility than the consensus reflects.
Key risk
If the company reports an EPS significantly above $9.00, it could challenge current market assumptions about growth.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it will set the tone for future growth and market confidence.
Bull confirmed if
An EPS of $9.00 or higher would confirm the bull case, indicating strong profitability.
Bear confirmed if
An EPS below $7.50 would confirm the bear case, suggesting potential issues in revenue generation.
What the market is pricing for the move.
Implied Move
±8.91%
Historical Avg
±8.0%
The options market is pricing in an expected move of about 8.91%, indicating that traders anticipate some volatility around the earnings announcement.
Options are pricing ±8.9% while LLY has averaged ±8.0% over the last 8 prints — setup is roughly in line with history.
ATM IV
0.4%
30d HV
21.8%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 12 of 30 (40%)
This setup has occurred 30 times across Health Care in the last 2 years. 12 of 30 faded and 18 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.4%, with a raw directional average of -0.4% (modestly negative historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
85.32%
of float
Insider
0.16%
of float
Holders
5,858
institutions
Top Holders· as of Jun 2026
Lilly Endowment, Inc
90,376,978 sh · $107.4B
9.60%
-1.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Eli Lilly beats expectations, history suggests a stock increase of around 3.0%, confirming its strong growth trajectory.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
If the company misses expectations, history suggests a potential decline of about 8.97%, raising concerns about its growth prospects.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
4
2 buys·2 sells
Members
3
House only
Est. Notional
$53,004.00–$145,000.00
disclosed dollar ranges
Most Active Members
2 trades
The lines on the call that would change the story.
Blackrock Inc.
67,540,400 sh · $80.3B
7.17%
1.8%
Vanguard Capital Management LLC
53,528,868 sh · $63.6B
5.69%
0.3%
PNC Financial Services Group, Inc.
51,322,720 sh · $61.0B
5.45%
-0.0%
State Street Corporation
36,215,754 sh · $43.1B
3.85%
1.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net buying
1 trade
Net selling
1 trade
Net selling
Recent Transactions
Traded Jul 10, 2026 · disclosed Jul 17, 2026
$1,001.00–$15,000.00
Traded Jul 1, 2026 · disclosed Aug 7, 2026
$1,001.00–$15,000.00
Traded Jun 10, 2026 · disclosed Jul 2, 2026
$50,001.00–$100,000.00
Traded Apr 14, 2026 · disclosed May 8, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.